Referred to the House Committee on Energy and Commerce.
This House resolution expresses support for designating April 5, 2025, as Barth Syndrome Awareness Day. It recognizes Barth syndrome as a rare, life‑threatening genetic disorder, notes diagnostic and treatment challenges, and encourages awareness, early diagnosis, research, and development of treatments and regulatory pathways for ultrarare diseases.
Emphasis on symbolism versus demand for funding and concrete action
Relative to its intended legislative type, this bill functions as a straightforward commemorative resolution: it identifies Barth syndrome, designates a specific awareness day, and enumerates areas of importance (awareness, diagnosis, research, treatment pathways).
This House resolution expresses support for designating April 5, 2025, as Barth Syndrome Awareness Day.
It recognizes Barth syndrome as a rare, life‑threatening genetic disorder, notes diagnostic and treatment challenges, and encourages awareness, early diagnosis, research, and development of treatments and regulatory pathways for ultrarare diseases.
H.Res is a non-binding House statement and does not create law; passage in the House is likely but it does not become statute.
Relative to its intended legislative type, this bill functions as a straightforward commemorative resolution: it identifies Barth syndrome, designates a specific awareness day, and enumerates areas of importance (awareness, diagnosis, research, treatment pathways). The form and level of detail are generally appropriate for a symbolic designation.
Emphasis on symbolism versus demand for funding and concrete action
These are examples from the analysis, not a ranked list of the most-affected groups.
Emphasis on symbolism versus demand for funding and concrete action
Generally supportive.
Views the resolution as a useful, nonbinding step to raise awareness, spotlight research gaps, and pressure regulators and funders to prioritize rare‑disease solutions.
May want stronger commitments on funding, equitable access, and protections against high drug prices.
Supportive but pragmatic.
Sees the resolution as a low‑cost, bipartisan way to raise visibility for a rare condition while noting it does not create programs or funding.
Wants clear next steps and careful balance between speeding approvals and ensuring safety.
Likely supportive of the awareness designation but cautious about policy implications.
Favors nonbinding recognition and private‑sector research; skeptical of expanded federal mandates or regulatory loosening.
Concerned about incentives that might increase drug costs or reduce approval rigor.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
H.Res is a non-binding House statement and does not create law; passage in the House is likely but it does not become statute.
The bill has not accumulated any surfaced votes yet.
Emphasis on symbolism versus demand for funding and concrete action
H.Res is a non-binding House statement and does not create law; passage in the House is likely but it does not become statute.
Relative to its intended legislative type, this bill functions as a straightforward commemorative resolution: it identifies Barth syndrome, designates a specific awareness day, and enumerates areas of importance (awaren…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.